IDWeek 2025

IDWeek 2025
October 18-22, 2025
Atlanta, GA, USA

IDWeek 2025.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (19)

    HIV VIEWPOINTS: SURVEY ON THE TREATMENT EXPERIENCES OF PEOPLE LIVING WITH HIV IN CANADA, MEXICO, AND THE UNITED STATES

    • Author(s): Guillaume, X
    • biktarvy
    • HIV / AIDS
    • Poster

    Antiretroviral Therapy Persistence Following a Change or Restart in Regimen Among People with HIV

    • Author(s): Chastek, B
    • biktarvy
    • HIV / AIDS

    Treatment Switch among Medicare-insured People with HIV and Gaps in Care

    • Author(s): Li, S
    • biktarvy
    • HIV / AIDS

    A Phase 1 Open-label, Parallel-group, Single- dose Study to Evaluate the Pharmacokinetics and Safety of Obeldesivir in Participants with Normal Renal Function and Renal Impairment

    • Author(s): Amini, E
    • obeldesivir
    • COVID-19

    Persistence and Adherence of People with HIV (PWH) and Mental Health Disorder Diagnosis who Restart Antiretroviral Therapy (ART)

    • Author(s): Lim, T
    • biktarvy
    • HIV / AIDS

    Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide From Cabotegravir + Rilpivirine: Results From the Phase 4 EMPOWER Study

    • Author(s): Gupta, S
    • biktarvy
    • HIV / AIDS

    No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1

    • Author(s): Potloane, D
    • yeztugo
    • HIV / AIDS

    No Clinically Significant Drug-Drug Interactions with Co-administration of Feminizing or Masculinizing Hormone Therapy and Twice- yearly Lenacapavir PrEP in Gender-Diverse Persons

    • Author(s): Blumenthal, J
    • yeztugo
    • HIV / AIDS

    Evaluation of Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir

    • Author(s): Niu, J
    • lenacapavir plus islatravir
    • HIV / AIDS

    Obeldesivir and GS-441524 Antiviral Activity against L Protein Mutants in Respiratory Syncytial Virus (RSV) Minigenome and Recombinant Infectious Virus Systems

    • Author(s): Moshiri, J
    • obeldesivir
    • gs-441524
    • COVID-19

    A Phase 4 Study to Evaluate the Safety and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV

    • Author(s): Walmsley, S
    • biktarvy
    • HIV / AIDS

    Remdesivir And Obeldesivir Retain Potent Activity Against SARS-CoV-2 Omicron variants

    • Author(s): Rodriguez,L
    • remdesivir
    • obeldesivir
    • COVID-19

    OBELDESIVIR CLINICAL DOSE PROJECTION FOR MARBURG VIRUS INFECTION POST-EXPOSURE PROPHYLAXIS

    • Author(s): Chang, J
    • obeldesivir
    • COVID-19

    Pooled Safety and Tolerability of Twice-Yearly Lenacapavir with Teropavimab and Zinlirvimab for HIV-1 Treatment

    • Author(s): Workowski, K
    • lenacapavir
    • zimberelimab
    • teropavimab
    • HIV / AIDS

    Dose Selection of Obeldesivir for Clinical Evaluation in Treatment of Adult Participants with Respiratory Syncytial Virus Infection

    • Author(s): Amini, E
    • obeldesivir
    • COVID-19

    Effectiveness of Remdesivir in Patients with Underlying Hepatic or Renal Comorbidity Hospitalized for SARS-CoV-2 Infection

    • Author(s): Berry, M
    • remdesivir
    • COVID-19

    SARS-CoV-2 Viral Load Dynamics in Participants With Solid Organ Transplantation and Severely Reduced Kidney Function From the Remdesivir Phase 3 REDPINE Study Who Were Hospitalized for COVID-19

    • Author(s): Rodriguez,L
    • remdesivir
    • COVID-19

    Influence of Nucleos(t)ide Analogue Use with Bulevirtide on Treatment Outcomes in Chronic Hepatitis Delta

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases

    Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab

    • Author(s): Zhang, N
    • lenacapavir
    • zimberelimab
    • teropavimab
    • HIV / AIDS